Drugs / SG2501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05293912 | Mar → Jun 2023 | lymphoma | Hangzhou Sumgen Biotech Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SG2501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293912 ↗ |
| Route | Intravenous | “via IV infusion” NCT05293912 ↗ |
| Target | CD38 | “Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody” NCT05293912 ↗ |
| Target | CD47 | “Recombinant Anti-cluster of Differentiation 38(CD38)/47(CD47) Bispecific Antibody” NCT05293912 ↗ |